A House committee investigating the safety and effectiveness of the popular cholesterol drug Vytorin and one of its components is turning up the heat on the drug's makers.
Falling oil prices helped lift stocks Monday, at the end of an otherwise abysmal quarter on Wall Street, marred by fears of a recession amid the housing crisis and credit market fallout.
U.S. stocks looked set for a mixed start on the last day of the quarter, as investors await a Bush administration plan aimed at overhauling regulation on Wall Street amid a meltdown in the financial sector.
Schering-Plough may have lost billions of dollars in the fourth quarter from an acquisition, but its stock jumped Tuesday as the drugmaker's earnings without charges beat expectations.
As Schering-Plough unveils full-year financial results for 2007 tomorrow, CEO Fred Hassan is likely to be peppered with questions about how he managed a recently released study of embattled cholesterol drug, Vytorin.
Is low cholesterol the pathway to a healthier heart? That's certainly what most medical experts - and their patients - have assumed for the last 30 years or so. But a recently-released study of Merck and Schering-Plough's cholesterol-lowering drug, Vytorin, is giving new voice to medical critics who have groused for decades about the questionable benefit of using medications to lower cholesterol and thereby prevent heart disease.
After the latest round of mixed earnings from the biggest players in pharma and biotech, companies are hampered by a frustrating dynamic: a product mix that isn't strong enough to match an exodus of blockbusters.
A House committee investigating the safety and effectiveness of the popular cholesterol drug Vytorin and one of its components is turning up the heat on the drug's makers.
Falling oil prices helped lift stocks Monday, at the end of an otherwise abysmal quarter on Wall Street, marred by fears of a recession amid the housing crisis and credit market fallout.
U.S. stocks looked set for a mixed start on the last day of the quarter, as investors await a Bush administration plan aimed at overhauling regulation on Wall Street amid a meltdown in the financial sector.
Schering-Plough may have lost billions of dollars in the fourth quarter from an acquisition, but its stock jumped Tuesday as the drugmaker's earnings without charges beat expectations.
As Schering-Plough unveils full-year financial results for 2007 tomorrow, CEO Fred Hassan is likely to be peppered with questions about how he managed a recently released study of embattled cholesterol drug, Vytorin.
Is low cholesterol the pathway to a healthier heart? That's certainly what most medical experts - and their patients - have assumed for the last 30 years or so. But a recently-released study of Merck and Schering-Plough's cholesterol-lowering drug, Vytorin, is giving new voice to medical critics who have groused for decades about the questionable benefit of using medications to lower cholesterol and thereby prevent heart disease.
After the latest round of mixed earnings from the biggest players in pharma and biotech, companies are hampered by a frustrating dynamic: a product mix that isn't strong enough to match an exodus of blockbusters.
Government regulators said Friday they are analyzing recent study results regarding cholesterol drug Vytorin, but that it's too early to tell whether it will take any regulatory action.
Stocks tanked Thursday afternoon after Federal Reserve Chairman Ben Bernanke urged lawmakers to enact a fiscal stimulus plan soon to help consumers and the economy.
Schering-Plough's stock almost crawled out of its hole Wednesday after a two-day lashing sparked by the results of a cholesterol drug trial, but the shares fell just before the market's close.
Drugmaker Schering-Plough is a favorite of analysts and investors these days. It's no wonder: The company's flagship product, the cholesterol-fighting Vytorin, is breaking sales records and faces relatively little risk from cheaper generic versions from rivals.
Schering-Plough Corp. said Monday that second-quarter earnings rose sharply, fueled by growing demand for its Zetia and Vytorin cholesterol drugs and treatments for arthritis and allergies.
All this reading of the tea leaves of Fed meeting minutes makes my brain hurt! I mean talk about white noise. Here's a question: Will the action pick up after Labor Day?
Merck and Schering-Plough announced a study on Sunday showing that their combination drug Vytorin is better at lowering cholesterol than competing drug Crestor from AstraZeneca.
Merck and Schering-Plough fired a shot across Pfizer's bow in the battle for control of the lucrative $25 billion cholesterol market with a new study saying their product is better for diabetics.
A new study shows that Vytorin, a cholesterol drug from Merck and Schering-Plough that combines Zocor and Zetia, significantly reduces cholesterol when compared to Zocor alone, the company said.
Vytorin, a relatively new cholesterol-blocking drug from Merck and Schering-Plough, has outpaced sales of a blockbuster rival, according to a report Monday from Friedman, Billings, Ramsey & Co.
Sales for Vytorin, a cholesterol-treating combination produced by Merck and Schering-Plough, have grown since its market debut last summer, but the drug's real test lies ahead, analysts say.
The page you requested cannot be found. The page you are looking for might have been removed, had its name changed, or is temporarily unavailable.
Please try the following:
• If you typed the page address in the Address bar, make sure that it is spelled correctly.
• Open the edition.cnn.com home page and look for links to the information you want.
• Use the navigation bar above to find the link you are looking for.
• Click the Back button to try another link.
• Enter a term in the search form below to look for information on CNN sites or the Internet.
Video
